MRI and PET to Assess Pembrolizumab Response

NCT02591654 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Poor enrollment

Conditions

Malignant Melanoma, Metastatic

Interventions

DRUG: Pembrolizumab
DRUG: FLT PET

Sponsor

Columbia University

Collaborators

[object Object]